Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study

Myers, S. D., Bradwell, A. R., Ashdown, K., Rue, C., Delamere, J., Thomas, O. D., Lucas, S. J. E., Wright, A. D. and Harris, S. J. (2018) Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study. BMJ open sport & exercise medicine, 4 (1). pp. 1-7. ISSN 2055-7647

[thumbnail of This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license]
Preview
Text (This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license)
e000302.full.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (444kB) | Preview

Abstract

To assess whether acetazolamide (Az), used prophylactically for acute mountain sickness (AMS), alters exercise capacity at high altitude.Az (500 mg daily) or placebo was administered to 20 healthy adults (aged 36±20 years, range 21-77), who were paired for age, sex, AMS susceptibility and weight, in a double-blind, randomised manner. Participants ascended over 5 days to 4559 m, then exercised to exhaustion on a bicycle ergometer, while recording breath-by-breath gas measurements. Comparisons between groups and matched pairs were done via Mann-Whitney U and Pearson's χ2 tests, respectively.Comparing paired individuals at altitude, those on Az had greater reductions in maximum power output (Pmax) as a percentage of sea-level values (65±14.1 vs 76.6±7.4 (placebo); P=0.007), lower VO2max (20.7±5.2 vs 24.6±5.1 mL/kg/min; P<0.01), smaller changes from rest to Pmax for VO2 (9.8±6.2 vs 13.8±4.9 mL/kg/min; P=0.04) and lower heart rate at Pmax (154±25 vs 167±16, P<0.01) compared with their placebo-treated partners. Correlational analysis (Pearson's) indicated that with increasing age Pmax (r=-0.83: P<0.005) and heart rate at Pmax (r=-0.71, P=0.01) reduced more in those taking Az.Maximum exercise performance at altitude was reduced more in subjects taking Az compared with placebo, particularly in older individuals. The age-related effect may reflect higher tissue concentrations of Az due to reduced renal excretion. Future studies should explore the effectiveness of smaller Az doses (eg, 250 mg daily or less) in older individuals to optimise the altitude-Az-exercise relationships.

Publication Type: Articles
Additional Information: ** From Europe PMC via Jisc Publications Router. ** Licence for this article: cc by-nc Article reuse is allowed pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC BY-NC 4.0) licence.
Uncontrolled Keywords: Altitude, Exercise, Elderly people
Subjects: G Geography. Anthropology. Recreation > GV Recreation Leisure > GV557 Sports
R Medicine > RC Internal medicine > RC1200 Sports Medicine
Divisions: Academic Areas > Institute of Sport > Area > Exercise Physiology
SWORD Depositor: Publications Router Jisc
Depositing User: Publications Router Jisc
Date Deposited: 03 May 2018 15:59
Last Modified: 03 Mar 2021 16:00
URI: https://eprints.chi.ac.uk/id/eprint/3340

Actions (login required)

View Item
View Item
▲ Top

Our address

I’m looking for